Inmune Bio Files 8-K: Financial Statements & Exhibits
Ticker: INMB · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
Related Tickers: INMB
TL;DR
INMB filed an 8-K with financial statements and exhibits. Nothing major disclosed.
AI Summary
On September 26, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a specific material event. No significant new financial figures or operational changes were detailed in the provided excerpt.
Why It Matters
This filing indicates Inmune Bio, Inc. is providing updated financial statements and exhibits to the SEC, which is a standard procedural requirement for public companies.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any new material events, risks, or significant financial changes.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- September 26, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-38793 (identifier) — Commission File Number
- 47-5205835 (identifier) — IRS Employer Identification No.
- 225 NE Mizner Blvd. , Suite 640 , Boca Raton , Florida 33432 (address) — Principal Executive Offices
- 858-964-3720 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Inmune Bio, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and to provide 'Financial Statements and Exhibits' as of September 26, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on September 26, 2024.
In which state is Inmune Bio, Inc. incorporated?
Inmune Bio, Inc. is incorporated in Nevada.
What is the principal executive office address for Inmune Bio, Inc.?
The principal executive office address is 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
Does this filing indicate any new material business developments or financial results?
Based on the provided excerpt, the filing primarily concerns routine reporting of financial statements and exhibits, and does not detail any new material business developments or specific financial results.
Filing Stats: 475 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-09-26 16:00:19
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0215822-8k_inmune.htm (8-K) — 25KB
- ea021582201ex99-1_inmune.htm (EX-99.1) — 11KB
- ex99-1.jpg (GRAPHIC) — 5KB
- 0001213900-24-082225.txt ( ) — 218KB
- inmb-20240926.xsd (EX-101.SCH) — 3KB
- inmb-20240926_lab.xml (EX-101.LAB) — 33KB
- inmb-20240926_pre.xml (EX-101.PRE) — 22KB
- ea0215822-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On September 26, 2024, INmune Bio Inc. (the "Company"), issued a press release announcing that the Company is continuing to advance its natural killer cell therapy, INKmune, in a Phase I/II trial for men with metastatic castration-resistant prostate cancer. In that same press release, the Company also announced initial results from the first patient cohort in the trial. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated September 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: September 26, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2